Allergy Therapeutics has concluded a successful end-of-Phase II meeting with the FDA for its ultra short course grass pollen allergy vaccine Pollinex Quattro.
Following a broad ranging review of Pollinex Quattro's preclinical, manufacturing and clinical data, and, subject to minor clarifications, the FDA has accepted the company's plans to conduct a single pivotal Phase III trial for registration of Pollinex Quattro Grass.